Thus, therapeutic interventions that reduce NOXA1/NOX1 activation and ROS generation in renal epithelial cells and thereby inhibit ENaC hyperactivity may be advantageous in the treatment of chronic kidney disease, diabetes, and therapy resistant HTN. Here, NOXA1 is linked to hypertensive disorder.